









# Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington's disease: A prospective, randomised, controlled, international, multi-centre study (HD-DBS)

	T
	Prospective, randomised, double blind, parallel group, sham-controlled,
STUDY DESIGN	multi-centre superiority trial.
	Billian de la contratición de la
	Bilateral stereotactic implantation of quadripolar electrodes (Medtronic
TREATMENT	Inc., 3387) into the GP and ACTIVA® PC stimulator for chronic high-
	frequency stimulation.
	to show superiority of DBS on motor function in the stimulation
	group compared to stimulation-off group
AIM OF THE STUDY	to show, that DBS is an alternative to medication therapy
	to prove the efficacy and safety of pallidal DBS in HD patients
	Difference between groups in the UHDRS total motor score (UHDRS-
PRIMARY ENDPOINT	TMS) at 12 weeks postoperatively compared to baseline.
	, , , , , , , , , , , , , , , , , , , ,
	Clinically symptomatic and genetically confirmed HD (number of
CRITERIA FOR INCLUSION	CAG repeats ≥ 36)
	Age ≥18 years
	<ul> <li>Moderate stage of the disease (UHDRS motor score ≥ 30)</li> </ul>
	Chorea despite best medical treatment (UHDRS chorea subscore
	≥ 10)
	<ul> <li>Mattis Dementia Rating Scale ≥ 120 (or &gt; 80% of items testable</li> </ul>
	independently from motor impairment)
	Patient has stable medication prior six weeks before inclusion     Signal informed consent.
	Signed informed consent     Westphal variant) or productional bradykingsia
	<ul> <li>Juvenile HD (Westphal variant) or predominant bradykinesia</li> <li>Postural instability with UHDRS retropulsion score &gt; 2</li> </ul>
	Severe comorbidity compromising operability and/or life
	expectancy and/or quality of life during the trial duration (e.g.
	cancer with life expectancy < 6 months, NYHA 3 and 4 rising the
	anaesthetic risk according to the anaesthesiologist)
	Acute suicidality
CRITERIA FOR EXCLUSION	Acute psychosis (symptoms within previous 6 months)
	Participation in any interventional clinical trial within 2 months
	before screening
	Cortical atrophy grade 3
	Patients with risk of coagulopathies and/or increased risk of
	haemorrhage
	Patients with an implanted pacemaker or defibrillator
	Pregnancy and lactation

### Contact details:

#### **Questions in general:**

### Jan Vesper(Düsseldorf)

Tel.: +49 211 81 18408

Mobil: +49 (0) 151 64936249

jan.vesper@med.uni-duesseldorf.de

## **Alfons Schnitzler (Düsseldorf)**

Tel.: +49 211 81-17893

Schnitza@med.uni-duesseldorf.de

### **General EHDN Contact for HD-DBS:**

## Pauline Kleger (EHDN)

Tel.: +49 731 50063106 Mobile: +49 174 9404718

Pauline.Kleger@uniklinik-ulm.de

### **Further information:**

https://www.euro-hd.net/html/projects/dbs